We are live on ! Find out more
IBRX icon

ImmunityBio
IBRX

149 hedge funds and large institutions have $200M invested in ImmunityBio in 2022 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 44 increasing their positions, 39 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

45% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 20

13% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 39

6% more funds holding

Funds holding: 141 → 149 (+8)

0.28% more ownership

Funds ownership: 8.67% → 8.95% (+0.28%)

5% less capital invested

Capital invested by funds: $209M → $200M (-$9.54M)

45% less call options, than puts

Call options by funds: $2.39M | Put options by funds: $4.31M

Holders
149
Holders Change
+8
Holders Change %
+5.67%
% of All Funds
2.35%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
29
Increased
44
Reduced
39
Closed
20
Calls
$2.39M
Puts
$4.31M
Net Calls
-$1.92M
Net Calls Change
+$2.51M

Top Buyers

1
Morgan Stanley
Morgan Stanley
New York
+$3.93M
2
State Street
State Street
Massachusetts
+$3.34M
3
OIM
Oracle Investment Management
Connecticut
+$2.45M
4
Millennium Management
Millennium Management
New York
+$2.04M
5
Citadel Advisors
Citadel Advisors
Florida
+$1.9M

Top Sellers

1
Renaissance Technologies
Renaissance Technologies
New York
-$1.85M
2
Citigroup
Citigroup
New York
-$1.78M
3
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$1.44M
4
BlackRock
BlackRock
New York
-$1.4M
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$1.13M
Name Holding Trade Value Shares
Change 		Change in
Stake
VF
101
Virtu Financial
New York
$74K -$105K -17,060 -56%
Commonwealth Equity Services
102
Commonwealth Equity Services
Massachusetts
$73K +$80.4K +13,108 New
Osaic Holdings
103
Osaic Holdings
Arizona
$69K +$4.63K +754 +6%
Barclays
104
Barclays
United Kingdom
$66K +$71.4K +11,641 New
TI
105
Tidal Investments
Wisconsin
$63K +$68.8K +11,219 New
WE
106
Wealth Effects
Massachusetts
$62K +$67.5K +11,000 New
CA
107
Claro Advisors
Massachusetts
$61K – – –
SPC
108
Sigma Planning Corp
Michigan
$59K +$64.1K +10,450 New
AB
109
Amalgamated Bank
New York
$48K +$52.6K +8,577 New
AF
110
Amalgamated Financial
New York
$48K +$52.6K +8,577 New
IUHSA
111
Itau Unibanco Holding S.A.
Brazil
$45K – – –
Victory Capital Management
112
Victory Capital Management
Texas
$43K +$1.52K +248 +2%
PHK
113
Point72 Hong Kong
Hong Kong
$34K +$36K +5,874 +2,136%
AW
114
Alaethes Wealth
Nevada
$29K – – –
AIP
115
Ameritas Investment Partners
Nebraska
$29K – – –
MLICM
116
Metropolitan Life Insurance Company (MetLife)
New York
$26.1K -$87.3K -14,225 -75%
S
117
SignatureFD
Georgia
$22K – – –
CG
118
Cutler Group
California
$14K +$14.3K +2,325 +700%
CAPTRUST Financial Advisors
119
CAPTRUST Financial Advisors
North Carolina
$11K – – –
ZIG
120
Zullo Investment Group
Pennsylvania
$11K – – –
Federated Hermes
121
Federated Hermes
Pennsylvania
$11K +$18 +3 +0.2%
National Bank of Canada
122
National Bank of Canada
Quebec, Canada
$10K – – –
PFS
123
Prospera Financial Services
Texas
$9K +$9.56K +1,559 New
Nisa Investment Advisors
124
Nisa Investment Advisors
Missouri
$9K +$9.82K +1,600 New
Rockefeller Capital Management
125
Rockefeller Capital Management
New York
$8K – – –
3 4
5
6 7

IBRX Hedge Fund Activity: Q1 2022 in Review

149 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in ImmunityBio (IBRX) for Q1 2022, worth a combined $200M — down 4.6% from $209M a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new IBRX positions and 20 closed out — a net gain of 9 holders — while 44 added to existing stakes and 39 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $3.93M. The largest seller was Renaissance Technologies, exiting entirely with an estimated $1.85M sold.

  • 149 institutional investors held ImmunityBio (IBRX) as of Q1 2022, up from 141 in Q4 2021.
  • Funds reported $200M of ImmunityBio stock for Q1 2022, down 4.6% quarter-over-quarter.
  • 29 funds opened new ImmunityBio positions in Q1 2022 and 20 closed out, a net change of +9 holders.
  • The largest ImmunityBio buyer in Q1 2022 was Morgan Stanley, an estimated $3.93M added.
  • The largest ImmunityBio seller in Q1 2022 was Renaissance Technologies, an estimated $1.85M sold.

Based on aggregated 13F filings for Q1 2022.